Skip to search formSkip to main contentSkip to account menu

CT 2584

Known as: CT-2584, CT2584, CT2584 HMS 
A substance that is being studied in the treatment of cancer. It may prevent the growth of blood vessels from surrounding tissue into a solid tumor.
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

Apra

Broader (1)

Xanthines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
CT-2584 (Cell Therapeutics).
  • R. Bonfil
  • Current opinion in investigational drugs
  • 2001
  • Corpus ID: 22139733
CT-2584, an anticancer agent that inhibits phospholipid signaling, is under development by Cell Therapeutics Inc (CTI) as a… 
2001
2001
CT-2584 (Cell Therapeutics).
2000
2000
Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines.
De novo production of phosphatidic acid (PA) in tumor cells is required for phospholipid biosynthesis and growth of tumor cells… 
2000
2000
Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours
CT-2584 HMS, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine-hydrogen methanesulphonate, is a modulator of… 
1999
1999
Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatography assay for the novel antitumour agent CT2584 in human plasma.
Highly Cited
1997
Highly Cited
1997
Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses.
1997
1997
Effect of a xanthine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice
Hepatocellular carcinoma (HCC) frequently overexpresses the MDR1 gene and is resistant to drugs transported by the multidrug… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License